JAK-STAT signaling pathway in cancer: from molecular mechanisms to clinical intervention Authors: Xiaoqian Zhang, Penghui Li, Fuqiang Ma, Tuokai Wang, Qingfei Chu, Shihui Wei, Chen Xue, Ziming Wang, Juan Lu Published: 2026 ABSTRACT The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway is a conserved signaling network that mediates communication between extracellular cytokine stimulation and nuclear transcriptional responses. Beyond its established role in regulating cell proliferation, differentiation, immune responses, and tissue homeostasis, dysregulated JAK/STAT signaling contributes to tumor progression, immune evasion, therapeutic resistance, and remodeling of the tumor microenvironment (TME). Although canonical ligand-dependent JAK/STAT activation has been extensively characterized, increasing evidence indicates that STAT proteins also participate in diverse non-canonical signaling processes, including organelle-associated localization, liquid-liquid phase separation, epigenetic regulation, and JAK-independent activation. These mechanisms expand the functional complexity and context dependence of JAK/STAT signaling in cancer biology. Within the TME, persistent pathway activation modulates dynamic interactions among tumor cells, immune cells, and stromal components, thereby promoting immunosuppressive signaling networks and therapeutic resistance. In this review, we summarize current understanding of canonical and non-canonical JAK/STAT signaling mechanisms, regulatory networks governing pathway activation, and the multifaceted roles of JAK/STAT signaling in tumor progression and therapeutic resistance. We further discuss emerging therapeutic strategies targeting the JAK/STAT pathway, including selective kinase inhibitors, STAT-directed therapies, epigenetic modulators, and combination immunotherapeutic approaches, together with the major translational challenges that continue to limit clinical efficacy. Introduction The Janus kinase/signal transducer and activator of transcription (JAK-STAT) signaling pathway is an evolutionarily conserved signaling cascade that mediates rapid communication between extracellular cytokine or growth factor stimulation and nuclear transcriptional responses [1, 2]. Initially characterized through studies of interferon (IFN)-responsive transcription, the pathway is now recognized as a central signaling mechanism utilized by numerous cytokines, interleukins, and growth factors to regulate cellular proliferation, differentiation, metabolism, immune responses, and tissue homeostasis [3]. Canonical JAK/STAT signaling involves ligand-induced receptor activation, recruitment of JAK family kinases, phosphorylation of STAT transcription factors, and subsequent transcriptional regulation of target genes. Dysregulation of JAK/STAT signaling has been implicated in a broad spectrum of solid tumors and hematologic malignancies through mechanisms including activating mutations, chronic inflammatory stimulation, epigenetic dysregulation, and loss of endogenous negative regulators [4, 5]. Persistent activation of JAK and STAT family members not only promotes tumor cell proliferation and survival but also contributes to immune evasion, therapeutic resistance, metabolic adaptation, and remodeling of the tumor microenvironment (TME) [6]. In recent years, growing evidence has revealed diverse non-canonical functions of JAK/STAT signaling, including organelle-associated localization, liquid-liquid phase separation, post-transcriptional regulation, and JAK-independent STAT activation, highlighting the complexity and context dependence of this signaling network. Therapeutic strategies targeting the JAK/STAT pathway have consequently evolved beyond conventional kinase inhibition. In addition to clinically approved JAK inhibitors such as ruxolitinib and tofacitinib, increasing attention has focused on selective STAT inhibitors, epigenetic modulators, targeted protein degraders, antisense oligonucleotides, and combination immunotherapeutic approaches [7, 8]. At the same time, important challenges remain, including pathway redundancy, compensatory signaling activation, systemic toxicity, intra-tumoral heterogeneity, and resistance to therapy. In this review, we summarize the canonical and non-canonical mechanisms of JAK/STAT signaling in cancer, with particular emphasis on tumor microenvironment remodeling, immune regulation, therapeutic resistance, and emerging targeted therapeutic strategies. We further discuss unresolved biological questions and translational challenges that continue to influence the development of effective JAK/STAT-directed therapies in oncology. JAK-STAT signaling pathway: composition and function Effective communication among cells and between cells and the extracellular environment is crucial for organism growth and development, homeostasis, and host defense. The JAK-STAT signaling pathway is one of the simplest paradigms in structure that can achieve direct communication between the extracellular environment and the cell nucleus. This section outlines the core compositions of the JAK and STAT families (Table 1), and elucidates molecular mechanisms governing both the classical and non-classical JAK-STAT signaling pathways. Table 1Core characteristics of JAKs and STATs family membersJAKs and STATsGenetic mappingPhosphorylation siteAssociated cytokineExpressed cellsRefs.JAK1Human 1p31.3Y1034/Y1035Y1038/Y1039IL-2, IL-4, IL-6, IL-7, IL-9, IL-10, IL-11, IL-15, IL-19, IL-20, IL-21, IL-24, IL-28, IL-29, IFNα/β, IFNγ, CNTF, OSM, LIF, CT-1Almost all nucleated cells (Hematopoietic cells, Epithelial cells, Endothelial cells, etc.)[239–242]JAK2Human 9p24Y1007/Y1008IL-3, IL-5, IL-6, IL-10, IL-11, IL-12, IL-13, IL-19, IL-20, IL-22, IL-23, IL-27, GH, EPO, TPO, PRL, Leptin, G-CSF, GM-CSF, IFNγHematopoietic cells (Erythrocyte lineage, Granulocyte lineage, Megakaryocyte lineage, Hematopoietic stem cells), Mammary epithelial cells[107, 243]JAK3Human 19p13.1Y980/Y981IL-2, IL-4, IL-7, IL-9, IL-15, IL-21Lymphocytes (T cells, B cells, NK cells)[244–246]TYK2Human 19p13.2Y1054/Y1055IL-6, IL-10, IL-11, IL-12, IL-13, IL-19 IL-20, IL-22, IL-23, IL-27, IL-28, IL-29, IFNα/β, IFNγImmune cells (Macrophages, Dendritic cells, T/B cells), Epithelial cells, Fibroblasts[239, 247]STAT1Human2q32.2-q32.3Y701IL-2, IL-6, IL-10, IL-11, IL-22, IL-27, IL-28, IL-29, IFNα/β, IFNγ, PDGF, EGF, HGF, TNF, TPO, Ang ⅡAlmost all nucleated cells[248, 249]STAT2Human12q13.3Y690IL-28, IL-29, IFNα/βImmune cells (Macrophages, Dendritic cells), Epithelial cells, Liver cells[250–252]STAT3Human17q21Y705IL-2, IL-3, IL-5, IL-6, IL-7, IL-9, IL-10, IL-11, IL-15, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-26, IL-27, IL-28, IL-29, IL-31, IFNα/β, LIF, CNTF, CT-1, GH, TPO, G-CSF, LeptinAlmost all nucleated cells (Immune cells, Tumor cells, Stem cells)[8, 239]STAT4Human2q32.2-q32.3Y693IL-12, IL-23, IL-27, IFNα/βT cells (Th1 subset), NK cells, Dendritic cells[248, 253, 254]STAT5a/bHuman17q21.32Y694/Y699IL-2, IL-3, IL-4, IL-5, IL-7, IL-9, IL-10, IL-15, IL-21, IL-22, IL-27, IL-28, IL-29, EGF, EPO, G-CSF, G-CM-CF, TPO, GH, PDGF, PRL, LeptinHematopoietic cells (T cells, B cells, Erythrocyte system, Granulocyte system), Prostate cells, Liver cells, Breast epithelial cells[8, 255–257]STAT6Human12q13.3-q14.1Y641IL-3, IL-4, IL-5, IL-13T cells (Th2 subset), B cells, Mast cells, eosinophils[253, 258, 259] Table 1Core characteristics of JAKs and STATs family membersJAKs and STATsGenetic mappingPhosphorylation siteAssociated cytokineExpressed cellsRefs.JAK1Human 1p31.3Y1034/Y1035Y1038/Y1039IL-2, IL-4, IL-6, IL-7, IL-9, IL-10, IL-11, IL-15, IL-19, IL-20, IL-21, IL-24, IL-28, IL-29, IFNα/β, IFNγ, CNTF, OSM, LIF, CT-1Almost all nucleated cells (Hematopoietic cells, Epithelial cells, Endothelial cells, etc.)[239–242]JAK2Human 9p24Y1007/Y1008IL-3, IL-5, IL-6, IL-10, IL-11, IL-12, IL-13, IL-19, IL-20, IL-22, IL-23, IL-27, GH, EPO, TPO, PRL, Leptin, G-CSF, GM-CSF, IFNγHematopoietic cells (Erythrocyte lineage, Granulocyte lineage, Megakaryocyte lineage, Hematopoietic stem cells), Mammary epithelial cells[107, 243]JAK3Human 19p13.1Y980/Y981IL-2, IL-4, IL-7, IL-9, IL-15, IL-21Lymphocytes (T cells, B cells, NK cells)[244–246]TYK2Human 19p13.2Y1054/Y1055IL-6, IL-10, IL-11, IL-12, IL-13, IL-19 IL-20, IL-22, IL-23, IL-27, IL-28, IL-29, IFNα/β, IFNγImmune cells (Macrophages, Dendritic cells, T/B cells), Epithelial cells, Fibroblasts[239, 247]STAT1Human2q32.2-q32.3Y701IL-2, IL-6, IL-10, IL-11, IL-22, IL-27, IL-28, IL-29, IFNα/β, IFNγ, PDGF, EGF, HGF, TNF, TPO, Ang ⅡAlmost all nucleated cells[248, 249]STAT2Human12q13.3Y690IL-28, IL-29, IFNα/βImmune cells (Macrophages, Dendritic cells), Epithelial cells, Liver cells[250–252]STAT3Human17q21Y705IL-2, IL-3, IL-5, IL-6, IL-7, IL-9, IL-10, IL-11, IL-15, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-26, IL-27, IL-28, IL-29, IL-31, IFNα/β, LIF, CNTF, CT-1, GH, TPO, G-CSF, LeptinAlmost all nucleated cells (Immune cells, Tumor cells, Stem cells)[8, 239]STAT4Human2q32.2-q32.3Y693IL-12, IL-23, IL-27, IFNα/βT cells (Th1 subset), NK cells, Dendritic cells[248, 253, 254]STAT5a/bHuman17q21.32Y694/Y699IL-2, IL-3, IL-4, IL-5, IL-7, IL-9, IL-10, IL-15, IL-21, IL-22, IL-27, IL-28, IL-29, EGF, EPO, G-CSF, G-CM-CF, TPO, GH, PDGF, PRL, LeptinHematopoietic cells (T cells, B cells, Erythrocyte system, Granulocyte system), Prostate cells, Liver cells, Breast epithelial cells[8, 255–257]STAT6Human12q13.3-q14.1Y641IL-3, IL-4, IL-5, IL-13T cells (Th2 subset), B cells, Mast cells, eosinophils[253, 258, 259] Core characteristics of JAKs and STATs family members Y1034/Y1035 Y1038/Y1039 IL-6, IL-10, IL-11, IL-12, IL-13, IL-19 IL-20, IL-22, IL-23, IL-27, IL-28, IL-29 , IFNα/β, IFNγ JAK family The JAK family comprises non-receptor tyrosine kinases that mediate signal transduction downstream of cytokine and growth factor receptors. JAK proteins were initially identified through studies investigating interferon-mediated transcriptional activation during the early 1990s. The JAK family includes JAK1, JAK2, JAK3, and TYK2. They act as intracellular adaptor proteins for transmitting cytokine signals and are present in various tissues [7, 8]. Among them, JAK3 is mainly found in hematopoietic and immune-related tissues, such as the bone marrow and lymphatic system, whereas other members are expressed in almost all tissues [9]. The JAK protein is composed of FERM, the Src-homology 2 (SH2) domain, pseudokinase, and kinase domains, and plays different roles in transmembrane signal transduction [8, 10]. FERM is a complex composed of four-point-one, ezrin, radixin, and moesin, with a cloverleaf structure [11, 12]. The FERM and SH2 domains primarily facilitate JAK binding to the receptor, and the pseudokinase domain regulates kinase activity and further phosphorylates downstream molecules. Structurally, JAK proteins contain four major functional domains: the FERM domain, SH2-like domain, pseudokinase domain (JH2), and catalytic kinase domain (JH1) [8, 10]. The FERM and SH2-like domains mediate receptor association, whereas the pseudokinase domain regulates catalytic activity of the adjacent kinase domain. The C-terminal kinase domain is responsible for phosphorylation of downstream substrates and initiation of STAT-dependent signaling. Cytokines (such as IFNs and ILs) and growth factors, along with their transmembrane receptors, are the main activators of JAK proteins. Ligand binding induces receptor conformational changes that activate receptor-associated JAK kinases, resulting in receptor phosphorylation and recruitment of downstream STAT proteins [13, 14]. Studies have found that JAK proteins regulate various biological processes and perform diverse functions. Although JAK family members exhibit overlapping signaling functions, JAK2 is strongly associated with hematopoietic regulation, whereas JAK1, JAK3, and TYK2 play broader roles in cytokine signaling and immune regulation [15–19]. STAT family STAT proteins function as the principal transcriptional effectors downstream of JAK-mediated cytokine signaling. The STAT family consists of STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6. STAT proteins contain several conserved functional domains, including N-terminal oligomerization regions, DNA-binding domains, SH2 domains, linker regions, and C-terminal transcriptional activation domains [8, 20]. Among these, the SH2 domain is essential for the recognition of phosphorylated receptor motifs and for STAT dimerization, whereas the transcriptional activation domain regulates the recruitment of co-activators and downstream gene transcription [8]. The N-terminal domain and the helical domain promote the formation of STAT dimers, enabling them to bind to transcription factors. The helical domain regulates nuclear entry. The DNA-binding domain can recognize and bind to DNA sequences in target gene regulatory regions and regulates nuclear entry. The linker domain structurally connects the DNA-binding domain and the SH2 domain. The SH2 domain of the STAT family is highly conserved and primarily functions to recognize specific phosphorylated tyrosine residues on cytokine receptors. The transcriptional activation domain is crucial for DNA transcription elements, for recruiting co-activators, and for regulating transcription through conserved serine phosphorylation sites [20]. Following receptor phosphorylation, STAT proteins are recruited to activated receptor complexes, undergo tyrosine phosphorylation, dimerize, and subsequently translocate to the nucleus where they regulate transcription of target genes. The dephosphorylated STATs exit from the nucleus and return to the cytoplasm. Different STAT proteins play distinct biological functions in signaling pathways. Individual STAT family members exhibit distinct but partially overlapping biological functions. STAT1 is primarily associated with interferon signaling, anti-viral responses, and anti-tumor immunity [21–25]. In contrast, STAT3 and STAT5 are more frequently linked to oncogenic signaling programs that regulate proliferation, survival, immunosuppression, and metastatic progression [26–31]. STAT4 and STAT6 mainly contribute to immune cell differentiation and cytokine-dependent immune regulation [28, 32, 33]. In addition to canonical JAK-dependent activation, several STAT proteins can also be activated through non-canonical mechanisms involving alternative oncogenic kinases and fusion proteins [34–40]. Notably, STAT1, STAT3, and STAT5 exhibit striking context-dependent and divergent roles in cancer. STAT1 primarily acts as a tumor suppressor by enhancing antitumor immunity, whereas STAT3 and STAT5 play oncogenic roles in most solid tumors and hematologic malignancies. Their functional switching is determined by cell type, cytokine stimuli, post-translational modifications, and subcellular localization, rather than a fixed pro-tumor or anti-tumor phenotype. The classical JAK-STAT signaling pathway Canonical JAK/STAT signaling follows a ligand-dependent cascade involving cytokine receptor activation, JAK-mediated phosphorylation, STAT dimerization, and transcriptional regulation of target genes [13]. Ligand binding induces conformational rearrangement or dimerization of cytokine receptors, thereby activating receptor-associated JAK kinases. In some signaling systems, including gp130- and EPOR-associated receptor complexes, inactive receptor dimers may pre-exist prior to ligand engagement, enabling rapid signal propagation in inflammatory, hematopoietic, and developmental contexts [41–47]. The ligand-to-receptor binding induces the phosphorylation of JAK proteins. Activated JAKs phosphorylate receptor-associated tyrosine residues, creating docking sites for STAT proteins. Subsequent STAT phosphorylation promotes homo- or heterodimer formation through SH2 domain interactions, enabling nuclear translocation and transcriptional activation of downstream target genes. These dimers translocate to the target gene promoter to regulate its transcription. After the transcription process is completed, dephosphorylated STATs exit the nucleus and return to the cytoplasm to continue participating in the next round of transcriptional activation. Within the nucleus, STAT proteins regulate gene expression either through direct DNA binding or through cooperative interactions with additional transcriptional regulators and chromatin-associated complexes [48–51]. A schematic overview of canonical JAK/STAT signaling is presented in Fig.1 . Fig. 1The complete process of cytokine signal transduction via the JAK-STAT pathway. (1) Receptor dimerization: Cytokines bind to their receptors on the cell membrane, inducing receptor dimerization. (2) JAK activation and phosphorylation: The dimerized receptors activate JAK kinases associated with their intracellular domains. JAKs undergo autophosphorylation and then further phosphorylate tyrosine residues on the intracellular segments of the receptors. (3) STAT recruitment and phosphorylation: Inactive STAT proteins in the cytoplasm bind to the phosphorylated tyrosine sites on the receptors via their SH2 domains and are subsequently phosphorylated by activated JAKs. (4) STAT dimerization: Phosphorylated STAT proteins undergo conformational changes and form homo- or heterodimers, becoming active transcription factor complexes. (5) Nuclear translocation and transcriptional regulation: Activated STAT dimers translocate into the nucleus, bind to STAT-binding sequences in the promoter regions of target genes, and initiate the transcription of cytokine-responsive genes, ultimately regulating biological functions such as cell proliferation and differentiation The complete process of cytokine signal transduction via the JAK-STAT pathway. (1) Receptor dimerization: Cytokines bind to their receptors on the cell membrane, inducing receptor dimerization. (2) JAK activation and phosphorylation: The dimerized receptors activate JAK kinases associated with their intracellular domains. JAKs undergo autophosphorylation and then further phosphorylate tyrosine residues on the intracellular segments of the receptors. (3) STAT recruitment and phosphorylation: Inactive STAT proteins in the cytoplasm bind to the phosphorylated tyrosine sites on the receptors via their SH2 domains and are subsequently phosphorylated by activated JAKs. (4) STAT dimerization: Phosphorylated STAT proteins undergo conformational changes and form homo- or heterodimers, becoming active transcription factor complexes. (5) Nuclear translocation and transcriptional regulation: Activated STAT dimers translocate into the nucleus, bind to STAT-binding sequences in the promoter regions of target genes, and initiate the transcription of cytokine-responsive genes, ultimately regulating biological functions such as cell proliferation and differentiation Non-classical JAK-STAT signaling pathway Although canonical JAK/STAT signaling accounts for most cytokine-mediated transcriptional responses, increasing evidence indicates that STAT proteins also participate in diverse non-canonical signaling processes (Fig. 2 ). These mechanisms frequently occur independently of classical tyrosine phosphorylation-dependent dimerization and nuclear translocation, thereby expanding the functional diversity of JAK/STAT signaling in cancer and immune regulation. Non-canonical STAT signaling has consequently emerged as an important area of investigation in tumor biology and therapeutic targeting. Fig. 2Mechanisms of non-classical JAK-STAT signaling and subcellular regulation. (A) Growth factor receptors (EGFR, PDGFR, HGFR) directly activate STAT1/5 independently of JAK at the plasma membrane. (B) Organelle-specific functions: ER-localized STAT3 promotes IP3R3 degradation, inhibiting Ca²⁺ overload and reducing ROS/apoptosis. Mitochondrial STAT3 interacts with ANT1 via MTS, regulating ADP/ATP exchange and promoting OXPHOS. Golgi-localized p-STAT6 regulates vesicle formation. (C) Nuclear non-canonical regulation: P300-mediated Lys-685 acetylation enables U-STAT3-driven Cyclin D1 transcription. LLPS-mediated droplets achieve rapid transcription by recruiting co-activators. PIAS-mediated SUMOylation inhibits DNA binding. (Top Right) Pathological/epigenetic regulation: DESI2 maintains JAK2-V617F stability; JAK2-mediated H3Y41 phosphorylation opens chromatin Mechanisms of non-classical JAK-STAT signaling and subcellular regulation. (A) Growth factor receptors (EGFR, PDGFR, HGFR) directly activate STAT1/5 independently of JAK at the plasma membrane. (B) Organelle-specific functions: ER-localized STAT3 promotes IP3R3 degradation, inhibiting Ca²⁺ overload and reducing ROS/apoptosis. Mitochondrial STAT3 interacts with ANT1 via MTS, regulating ADP/ATP exchange and promoting OXPHOS. Golgi-localized p-STAT6 regulates vesicle formation. (C) Nuclear non-canonical regulation: P300-mediated Lys-685 acetylation enables U-STAT3-driven Cyclin D1 transcription. LLPS-mediated droplets achieve rapid transcription by recruiting co-activators. PIAS-mediated SUMOylation inhibits DNA binding. (Top Right) Pathological/epigenetic regulation: DESI2 maintains JAK2-V617F stability; JAK2-mediated H3Y41 phosphorylation opens chromatin Non-phosphorylated STAT (U-STAT) can drive the transcription of target genes. P300-mediated acetylation of STAT3 at Lys685 has been reported to regulate Cyclin D1 expression independently of canonical STAT3 phosphorylation [52]. In addition to their cytoplasmic and nuclear functions, several STAT proteins exhibit organelle-associated localization and non-transcriptional regulatory activities [53]. STAT3 can be located in mitochondria and enters the inner membrane through the two mitochondrial targeting sequences (MTS) at the N-terminus, and mitochondrial STAT3 has been reported to interact with ANT1 [54]. Additionally, STAT3 can also localize to the endoplasmic reticulum, where it binds to the IP3R3 calcium channel and promotes its degradation, thereby inhibiting ER-to-mitochondria Ca²⁺ overload and oxidative stress-induced apoptosis; this function has been validated in breast tumor cells [55]. STAT6 has also been implicated in Golgi-associated signaling functions. Following IL-4 stimulation, phosphorylated STAT6 localizes to Golgi compartments where it participates in COPI vesicle formation and membrane trafficking processes [56]. In 2021, a study reported that the intrinsically disordered region of STAT3 can undergo liquid-liquid phase separation under specific cellular conditions, recruiting transcriptional co-activators and RNA Pol II to drive rapid transcription; phosphorylation or acetylation can regulate droplet size and solubility, thereby modulating transcription [57]. Collectively, these non-canonical signaling mechanisms, including acetylation-dependent regulation, organelle-associated localization, and liquid-liquid phase separation, expand the functional complexity of JAK/STAT signaling beyond the classical phosphorylation-dependent paradigm. These processes contribute to cellular adaptation under inflammatory, metabolic, and oncogenic stress conditions and may provide additional therapeutic opportunities for targeting cancer and immune-related diseases. Regulation and abnormal activation of the JAK-STAT signaling pathway JAK/STAT signaling is regulated through a dynamic balance between pathway activation, negative feedback inhibition, post-translational modification, and integration with other signaling networks [58]. Under physiological conditions, this regulatory architecture maintains controlled cytokine responsiveness and cellular homeostasis. In cancer and inflammatory diseases, however, genetic mutations, epigenetic dysregulation, chronic inflammatory signaling, and microenvironmental stress can disrupt these regulatory mechanisms, resulting in persistent pathway activation and aberrant transcriptional programs. Recent studies have further expanded understanding of JAK/STAT regulation by identifying context-dependent post-transcriptional, metabolic, and chromatin-associated mechanisms that contribute to signaling plasticity and therapeutic resistance. The following section summarizes the molecular mechanisms underlying positive regulation, negative regulation (Table 2), and abnormal activation of the JAK-STAT signaling pathway. Table 2JAK-STAT pathway regulatory mechanismsRegulatory typeRegulatory dimensionKey factors / pathwaysCore functionRef.Positive regulationPost-translational modificationDESI2DeSUMoylates JAK2-V617F, maintains its stability, and promotes pathway activation [59]Multi-path collaborationCa²⁺-WNT cross-talk signalingRegulates cytoplasmic calcium, affects WNT signaling, and modulates cell differentiation [60]Cell-specificityT cell subset preferenceDifferences in the activation patterns of immune cell subsets [61]Negative regulationSOCS familySOCS1/3 & CISInhibits JAK activity, blocks STAT recruitment, and mediates ubiquitination and degradation [64–67]PIAS familyPIAS3Blocks STAT-DNA binding and mediates SUMOylation modification [71, 72]PTPsSHP-1/2Dephosphorylates JAK/STAT and terminates pathway signaling [74, 75]Non-coding RNAmiR-124 & miR-155Targets mRNA and regulates pathway activity at the post-transcriptional level [100, 260]Epigenetic modificationDNA methylation & histone modificationRegulates the expression of negative regulators and inhibits excessive pathway activation [84, 85] Table 2JAK-STAT pathway regulatory mechanismsRegulatory typeRegulatory dimensionKey factors / pathwaysCore functionRef.Positive regulationPost-translational modificationDESI2DeSUMoylates JAK2-V617F, maintains its stability, and promotes pathway activation [59]Multi-path collaborationCa²⁺-WNT cross-talk signalingRegulates cytoplasmic calcium, affects WNT signaling, and modulates cell differentiation [60]Cell-specificityT cell subset preferenceDifferences in the activation patterns of immune cell subsets [61]Negative regulationSOCS familySOCS1/3 & CISInhibits JAK activity, blocks STAT recruitment, and mediates ubiquitination and degradation [64–67]PIAS familyPIAS3Blocks STAT-DNA binding and mediates SUMOylation modification [71, 72]PTPsSHP-1/2Dephosphorylates JAK/STAT and terminates pathway signaling [74, 75]Non-coding RNAmiR-124 & miR-155Targets mRNA and regulates pathway activity at the post-transcriptional level [100, 260]Epigenetic modificationDNA methylation & histone modificationRegulates the expression of negative regulators and inhibits excessive pathway activation [84, 85] JAK-STAT pathway regulatory mechanisms Positive regulation Positive regulation of JAK/STAT signaling involves coordinated activation of receptor-associated kinases, post-translational modifications, and integration with parallel signaling pathways. In addition to canonical cytokine-mediated activation, recent evidence suggests that pathway activity is dynamically shaped by protein stability mechanisms, SUMOylation, calcium signaling, and signaling crosstalk with other developmental and inflammatory pathways. Recent studies have found that the positive activation of JAK-STAT is not a single linear pathway but involves cross-interaction with other signaling networks. Yang et al. discovered through co-immunoprecipitation-mass spectrometry analysis that the de-SUMOylation enzyme DESI2 can act as a specific binding protein for the JAK2-V617F mutant by removing the SUMOylation modification at its K962 site, maintaining the stability of the mutant JAK2 protein, and indirectly promoting the continuous activation of the JAK-STAT signaling pathway [59]. These findings suggest that post-translational regulation of mutant JAK2 stability may contribute to sustained oncogenic signaling. Crosstalk between JAK/STAT signaling and other regulatory pathways further contributes to context-dependent pathway activation. For example, interactions between calcium signaling and WNT-associated transcriptional programs have been implicated in developmental signaling processes that regulate mesodermal differentiation and cell fate determination [60]. In immune cells, positive regulation exhibits cell-specific characteristics. A study of patients with rheumatoid arthritis showed that, in T cell subtypes with elevated STAT5a/b activity, activation of JAK3 by IL-2/IL-7 signals was significantly enhanced, whereas in myeloid cells, activation was mainly through JAK1/STAT1/STAT3, highlighting cell-type-specific patterns of JAK/STAT pathway activation [61]. Negative regulation Negative regulation of JAK/STAT signaling is essential for limiting excessive cytokine responsiveness and maintaining signaling homeostasis. Multiple inhibitory mechanisms—including SOCS-mediated feedback inhibition, PIAS-dependent transcriptional repression, phosphatase activity, and ubiquitin-mediated protein degradation—cooperate to terminate pathway activation and prevent sustained inflammatory or oncogenic signaling. The SOCS family is the most important negative regulatory factor in the JAK-STAT signaling pathway, comprising 8 members, including SOCS1-7 and CIS [62, 63]. Among them, the regulatory effects of SOCS1, SOCS3, and CIS have been extensively explored and clarified. SOCS proteins inhibit JAK/STAT signaling through several complementary mechanisms. These include direct inhibition of JAK catalytic activity, competition for phosphorylated receptor docking sites, and recruitment of ubiquitin ligase complexes that promote the degradation of JAK and STAT proteins [64–67]. SOCS3-mediated inhibition of JAK1/STAT3 signaling has also been implicated in regulating inflammatory responses in the central nervous system, highlighting broader homeostatic roles for this regulatory network [68, 69]. CIS can bind to phosphorylated STAT sites and inhibit STAT activation. CIS specifically inhibits the activation of STAT5 mediated by IL2/IL-3 through binding to the phosphorylated sites of STAT5 [70]. The PIAS family regulates STAT activity through multiple mechanisms, which is another important branch of negative regulation. The PIAS family consists of four members: PIAS1, PIAS3, PIASx, and PIASy. PIAS proteins suppress STAT activity through multiple mechanisms: first, by binding to STAT dimers and blocking their binding to DNA [71]; second, as a SUMO ligase, mediating the SUMOylation, modifying STAT, inhibiting its transcriptional activity [72]; third, by recruiting histone deacetylases to alter the local chromatin structure [71]. Altered PIAS expression under inflammatory and hypoxic conditions may weaken STAT inhibitory activity and contribute to the activation of pathological signaling [73]. Protein tyrosine phosphatases (PTPs) can terminate pathwaysignaling pathways by reversing phosphorylation. The SH domain in PTPs can bind to signaling molecules, activate receptors, and dephosphorylate JAK-dependent substrates. PTPs can dephosphorylate STAT and inhibit its activity, as well as inhibit JAK/STAT signal transduction. SHP-1, SHP-2, and PTP1B are the most studied subtypes. Among them, SHP-1 directly inhibits pathway activation by dephosphorylating the active sites of JAK and STAT [74, 75]. SHP-2 can negatively regulate the cytotoxic effect of IFN by inhibiting excessive STAT activation, thereby promoting cell growth [76]. Abnormal activation of the JAK-STAT signaling pathway Persistent activation of JAK/STAT signaling in cancer commonly arises through genetic mutations, epigenetic dysregulation, chronic inflammatory signaling, and microenvironment-associated stress responses. They mainly include activating mutations in JAKs and STATs, as well as inactivating mutations in negative regulatory factors. In hematological malignancies, the JAK2 V617F mutation is the most common, located in the JH2 self-inhibitory domain of JAK2. It leads to the release of self-inhibition, the continuous activation of JAK2, and the subsequent activation of downstream STAT3/STAT5 signaling, promoting abnormal cell proliferation [77]. The JAK2 V617F mutation can also induce conformational changes in the protein, enhancing its binding to DESI2. DESI2 inhibits the ubiquitination and degradation of JAK2 V617F via de-SUMOylation, thereby maintaining its activity and forming a positive feedback loop [59]. Activation mutations of STATs are also common. Activating mutations involving STAT family members can further sustain ligand-independent signaling. For example, the STAT3 Y640F mutation enhances STAT3 dimerization and constitutive nuclear localization, whereas activating STAT5 alterations have been implicated in persistent proliferative signaling in hematologic malignancies [78, 79]. Conversely, loss or inactivation of endogenous negative regulators such as SOCS family proteins can further amplify JAK/STAT pathway activation [80–83]. Epigenetic dysregulation also contributes substantially to persistent JAK/STAT activation through DNA methylation, histone modifications, and chromatin remodeling, which alter the expression of pathway regulators and downstream transcriptional programs. Promoter hypermethylation of negative regulators, including SOCS1 and SOCS3, can suppress their expression, thereby enhancing JAK/STAT pathway activity [84–91]. Restoration of SOCS expression using epigenetic therapies has correspondingly been associated with reduced tumor cell proliferation in experimental models. Collectively, these findings illustrate how epigenetic dysregulation may sustain persistent JAK/STAT activation. In Sézary syndrome and other T-cell leukemia, the frequent mutations of epigenetic modifiers further exacerbate the disorder of the JAK-STAT pathway, with the inactivation mutations of chromatin remodeling genes such as ARID1A and TET2 occurring at rates of over 40%, indirectly enhancing this pathway by altering the epigenetic landscape of the genome [92, 93]. Histone modifications further influence JAK/STAT signaling by regulating chromatin accessibility and transcriptional activity. Histone modification directly reshapes the activation state of the JAK-STAT pathway by regulating chromatin accessibility and transcription factor activity. The JAK2V617F mutation, as the core driver of polycythemia vera, can directly interfere with the balance of histone modification: on the one hand, it inhibits protein arginine methyltransferase 5 activity through phosphorylation, disrupting the normal histone methylation pattern [94]; on the other hand, it directly catalyzes the phosphorylation of tyrosine at position 41 of histone H3, opening the chromatin structure of hematopoietic-related target genes and promoting the abnormal proliferation of myeloid cells [95]. In synovial monocytes from patients with juvenile idiopathic arthritis, abnormal histone modifications, such as H3K27me3, lead to the epigenetic activation of IFN-related genes, thereby forming a persistent activated JAK-STAT signaling environment [96, 97]. Moreover, histone deacetylase inhibitors, such as givosiran, can regulate the histone acetylation state and reduce the level of JAK2-V617F protein, providing an epigenetic intervention target for the treatment of myeloproliferative neoplasms [98, 99]. Non-coding RNAs also contribute to aberrant JAK/STAT signaling through post-transcriptional regulation of pathway components and negative regulators. Several miRNAs, including miR-155 and miR-21, enhance pathway activation by suppressing inhibitory molecules such as SOCS1 and PTEN [100, 101]. In contrast, loss of regulatory miRNAs such as miR-124 has been associated with excessive inflammatory signaling through increased JAK1/STAT3 activity [102, 103]. Long non-coding RNAs can additionally establish positive feedback loops that sustain STAT-dependent transcriptional programs and inflammatory signaling [104, 105]. Microenvironment-associated inflammatory signaling also plays an important role in sustaining aberrant JAK/STAT activation. Within the tumor microenvironment, cytokines such as IL-6, derived from tumor-associated macrophages, can maintain chronic STAT3 signaling and promote tumor proliferation, invasion, and immunosuppression [106]. In parallel, hypoxia and inflammatory stress responses may activate JAK2/STAT5- and JAK1/STAT3-associated signaling programs in non-malignant tissues, further illustrating the context-dependent pathological consequences of persistent pathway activation [107–111]. The JAK-STAT signaling pathway and the biological functions of tumors JAK-STAT signaling pathway and tumor cells The JAK-STAT signaling pathway functions as a central regulator of malignant tumor cell behavior by integrating inflammatory signaling, oncogenic stress responses, and transcriptional reprogramming. Persistent activation of STAT3 and STAT5 signaling promotes tumor cell proliferation, survival, metabolic adaptation, stemness, and metastatic plasticity across multiple solid tumors and hematologic malignancies. In many cancers, constitutive pathway activation arises through a combination of oncogenic mutations, cytokine-driven autocrine signaling, and crosstalk with other oncogenic pathways, thereby sustaining chronic pro-survival and pro-invasive transcriptional programs [112–116]. Rather than functioning as an isolated signaling cascade, JAK-STAT signaling operates as a highly interconnected signaling hub that cooperates with NF-κB, Wnt/β-catenin, RAS/ERK, and PI3K/AKT/mTOR pathways to amplify tumor-promoting phenotypes [112–116]. This signaling convergence contributes not only to enhanced proliferation and resistance to apoptosis but also to epithelial-mesenchymal transition (EMT), cancer stem cell maintenance, angiogenesis, and therapeutic resistance. The IKKα/NF-κB axis can induce LIF expression, thereby transactivating STAT3 and further amplifying inflammatory and pro-survival signaling programs, while activation of Wnt signaling enhances JAK activity through upregulation of gp130 [117, 118]. This signaling convergence amplifies oncogenic transcriptional output and contributes to tumor progression, phenotypic plasticity, and therapeutic resistance [119–121]. The oncogenic output of JAK-STAT signaling is further shaped by epigenetic and post-transcriptional regulatory networks. DNA methylation-mediated silencing of negative regulators such as SOCS family members enhances constitutive pathway activation, while non-coding RNAs establish complex feedforward signaling circuits that reinforce STAT-dependent transcriptional programs [122–124]. In parallel, RNA methylation regulators and chromatin-modifying enzymes dynamically modulate JAK/STAT-dependent transcriptional plasticity, thereby influencing immune phenotypes, tumor cell differentiation states, and therapeutic responsiveness [124]. Collectively, these regulatory mechanisms stabilize persistent pathway activation and contribute to tumor heterogeneity and adaptive resistance. During the process by which tumor cells acquire the ability to invade and metastasize, the JAK-STAT signaling pathway also plays a commanding role. Its core mechanism involves epithelial-mesenchymal transition (EMT), extracellular matrix (ECM) remodeling, and angiogenesis. Activated STAT3 is a key inducer of the EMT program [125, 126]. In cervical cancer, HPV oncogenes E6/E7 rely on this pathway to deprive cells of their adhesion properties [127]. In non-small cell lung cancer, the compensatory activation of the JAK/STAT signaling pathway not only mediates adaptive resistance to ERK inhibitors but also simultaneously drives EMT and the expansion of cancer stem cells (CSCs) [128]. JAK/STAT signaling also interacts with DNA damage response pathways and immune regulatory programs, thereby influencing metastatic potential through coordinated regulation of EMT and PD-L1 expression [124, 129–131]. To break through the tissue barrier, the JAK-STAT signaling pathway directly upregulates the transcription of matrix metalloproteinase (MMP2/9) and cooperates with histone deacetylases (such as HDAC3) to promote the expression of MMP3/13 through epigenetic modifications, accelerating ECM degradation and the formation of bone metastasis foci [132–137]. Moreover, angiogenesis, as a necessary condition for metastasis, is also strictly regulated by this pathway. In breast cancer and pancreatic cancer models, the EGFR/JAK/STAT3 signaling axis directly upregulates the expression of VEGF and HIF-1α [138–140], while miR-301a and other oncogenic miRNAs further amplify the JAK/STAT3 signal by targeting and inhibiting SOCS5 [141], thereby constructing a highly vascularized microenvironment conducive to tumor dissemination [135, 142, 143]. Collectively, persistent JAK-STAT activation reshapes tumor cell phenotypes by coordinating the regulation of proliferation, survival, EMT, stemness, metabolic adaptation, and angiogenesis. These integrated signaling programs not only support malignant progression but also establish the molecular foundation for immune escape and therapeutic resistance, discussed in subsequent sections. Crosstalk between the JAK-STAT signaling pathway and immune cells and tumor cells The JAK-STAT signaling pathway plays a central role in coordinating interactions between tumor cells, immune cells, and stromal populations within the TME (Table 3). Through regulation of inflammatory signaling, antigen presentation, immune checkpoint expression, and myeloid cell polarization, persistent JAK/STAT activation contributes to immune suppression, tumor progression, and resistance to immunotherapy (Fig. 3). Consequently, aberrant JAK/STAT signaling links tumor-intrinsic oncogenic programs with dynamic remodeling of the immunosuppressive microenvironment. Within tumor cells, genetic and epigenetic alterations in the JAK/STAT pathway directly dictate their visibility to the immune system and their sensitivity to immune checkpoint blockade (ICB), highlighting the context-dependent effects of JAK/STAT signaling on anti-tumor immunity. In melanoma and glioma (e.g., the CT2A model), such mutations block downstream IFN-γ receptor signal transduction, preventing STAT1 activation. This profoundly downregulates MHC-I molecules and the antigen presentation machinery (APM, such as Tap1 and Psmb8), enabling tumor cells to successfully evade recognition and clearance by CD8 + T cells [144–148]. These alterations represent an important mechanism contributing to primary and acquired resistance to PD-1 blockade. On the other hand, aberrant overactivation of JAK/STAT signaling drives “adaptive immune resistance.” Multiple oncogenes and regulatory factors hijack this pathway to upregulate immune checkpoint molecules [149–153]. For instance, the E3 ubiquitin ligase HERC2 and RNA-binding protein RBM12 continuously activate the JAK/STAT1 or JAK/STAT3 axis. Activated STATs directly bind to the CD274 (PD-L1) promoter, significantly upregulating PD-L1 expression and inducing T cell exhaustion. Furthermore, in diffuse large B-cell lymphoma, the disruption of the “LYN-CD22-SHP1” inhibitory axis via CD58 loss blocks the negative regulation of JAK2/STAT1, leading to a compensatory upregulation of PD-L1 and IDO, thereby conferring intrinsic resistance to CAR-T therapy [154, 155]. Furthermore, antigen presentation is severely compromised. The TME tends to disrupt the balance between STAT3 and STAT5 within dendritic cells (DCs). Persistent JAK/STAT3 activation antagonizes STAT5-mediated DC maturation, inhibits antigen cross-presentation (downregulating CD80/CD86), and suppresses CTL activation [156]. Moreover, WNT2 secreted by cancer-associated fibroblasts (CAFs) upregulates SOCS3 in DCs, suppressing JAK2 signaling and depleting the CD103 + DC subset, which directly facilitates immune escape [157]. Fig. 3Mechanisms of JAK/STAT signaling-mediated immune evasion in the TME. (A) Intrinsic antigen presentation defect: JAK1/2 loss-of-function (LOF) mutations abrogate IFNγ receptor signaling, leading to the transcriptional downregulation of the antigen-processing machinery (APM) and MHC-I molecules, thereby facilitating evasion from CD8+ T-cell surveillance. (B) Adaptive resistance and T-cell exhaustion: Aberrant STAT1/3 activation drives PD-L1 expression, which interacts with PD-1 to induce T-cell exhaustion. This immunosuppressive state is further reinforced by tumor-derived exosomes and paracrine factors (CXCL16, HB-EGF). (C) Dendritic cell (DC) dysfunction: Fibroblast-derived WNT2 triggers SOCS3 expression in DCs, causing a STAT3/STAT5 signaling imbalance. This suppresses MHC and co-stimulatory molecule (CD80/86) expression, thereby impairing antigen cross-presentation. (D) Macrophage reprogramming and metabolic rewiring: The VSIG4-JAK-STAT3 axis, integrated with enhanced fatty acid oxidation (FAO), drives the M1-to-M2 phenotypic switch. These pro-tumorigenic M2 macrophages secrete CXCL16 and HB-EGF to inhibit T-cell infiltration and sustain a "cold" tumor microenvironment Mechanisms of JAK/STAT signaling-mediated immune evasion in the TME. (A) Intrinsic antigen presentation defect: JAK1/2 loss-of-function (LOF) mutations abrogate IFNγ receptor signaling, leading to the transcriptional downregulation of the antigen-processing machinery (APM) and MHC-I molecules, thereby facilitating evasion from CD8+ T-cell surveillance. (B) Adaptive resistance and T-cell exhaustion: Aberrant STAT1/3 activation drives PD-L1 expression, which interacts with PD-1 to induce T-cell exhaustion. This immunosuppressive state is further reinforced by tumor-derived exosomes and paracrine factors (CXCL16, HB-EGF). (C) Dendritic cell (DC) dysfunction: Fibroblast-derived WNT2 triggers SOCS3 expression in DCs, causing a STAT3/STAT5 signaling imbalance. This suppresses MHC and co-stimulatory molecule (CD80/86) expression, thereby impairing antigen cross-presentation. (D) Macrophage reprogramming and metabolic rewiring: The VSIG4-JAK-STAT3 axis, integrated with enhanced fatty acid oxidation (FAO), drives the M1-to-M2 phenotypic switch. These pro-tumorigenic M2 macrophages secrete CXCL16 and HB-EGF to inhibit T-cell infiltration and sustain a "cold" tumor microenvironment Table 3Intricate JAK-STAT-mediated intercellular crosstalk networks within the TMESignal-Initiating CellKey Signaling Molecule (Ligand/Exosome)Signal-Receiving CellIntracellular JAK-STAT AxisMajor Pro-tumorigenic/ Antitumorigenic EffectRef.Cancer CellsGM-CSFNeutrophilsJAK2-STAT5-C/EBPβInduced ACOD1 expression; promoted lung metastasis. [141]IL-6Microglia (Brain)JAK2-STAT3M2-like polarization; supported brain metastasis colonization. [146]PD-L1 (Reverse Signaling)Cancer Cells (Self)Intracellular JAK2-STAT3Induced IL-6 secretion; recruited MDSCs. [172, 173]Exosomes (miR-106a-5p)MacrophagesJAK2-STAT3 (SOCS6 inhibition)Induced M2 polarization; accelerated liver metastasis. [141, 147]TAMs (Macrophages)IL-6Cancer CellsJAK2-STAT3Promoted proliferation; inhibited miR-506-3p →FoxQ1 upregulation, enhancing metastasis. [145]CAFs (Fibroblasts)WNT2Dendritic Cells (DCs)JAK2 (via SOCS3 upregulation)reduced CD103 + DC subset; promoted immune escape [157]IL-6 (SASP Phenotype)Cancer Cells/MDSCs/TAMsJAK/STAT3 (Autocrine/Paracrine)Enhanced cancer cell vitality; driven immune-suppressive cell polarization [139, 140, 142, 148]T CellsCDCP1T Cells (Self, CTLs)JAK-STAT Axis (Inhibition)Attenuated cytolytic activity; induced Tregs function [160, 161]DCs (Dendritic Cells)IL-12 (Decreased secretion)CD8 + T CellsJAK-STAT Axis (Blockade)Abrogated CD8 + T cell cytotoxic activity [136] Table 3Intricate JAK-STAT-mediated intercellular crosstalk networks within the TMESignal-Initiating CellKey Signaling Molecule (Ligand/Exosome)Signal-Receiving CellIntracellular JAK-STAT AxisMajor Pro-tumorigenic/ Antitumorigenic EffectRef.Cancer CellsGM-CSFNeutrophilsJAK2-STAT5-C/EBPβInduced ACOD1 expression; promoted lung metastasis. [141]IL-6Microglia (Brain)JAK2-STAT3M2-like polarization; supported brain metastasis colonization. [146]PD-L1 (Reverse Signaling)Cancer Cells (Self)Intracellular JAK2-STAT3Induced IL-6 secretion; recruited MDSCs. [172, 173]Exosomes (miR-106a-5p)MacrophagesJAK2-STAT3 (SOCS6 inhibition)Induced M2 polarization; accelerated liver metastasis. [141, 147]TAMs (Macrophages)IL-6Cancer CellsJAK2-STAT3Promoted proliferation; inhibited miR-506-3p →FoxQ1 upregulation, enhancing metastasis. [145]CAFs (Fibroblasts)WNT2Dendritic Cells (DCs)JAK2 (via SOCS3 upregulation)reduced CD103 + DC subset; promoted immune escape [157]IL-6 (SASP Phenotype)Cancer Cells/MDSCs/TAMsJAK/STAT3 (Autocrine/Paracrine)Enhanced cancer cell vitality; driven immune-suppressive cell polarization [139, 140, 142, 148]T CellsCDCP1T Cells (Self, CTLs)JAK-STAT Axis (Inhibition)Attenuated cytolytic activity; induced Tregs function [160, 161]DCs (Dendritic Cells)IL-12 (Decreased secretion)CD8 + T CellsJAK-STAT Axis (Blockade)Abrogated CD8 + T cell cytotoxic activity [136] Intricate JAK-STAT-mediated intercellular crosstalk networks within the TME Alongside DC dysfunction, macrophage reprogramming plays a critical role. Notably, the PD-1/VSIG4-JAK2-STAT3-fatty acid oxidation (FAO) axis illustrates how immune checkpoint signaling and metabolic adaptation synergistically promote M2 polarization and suppress anti-tumor immunity. These macrophages secrete factors including CXCL16 and HB-EGF, thereby contributing to formation of “cold” tumor niches characterized by reduced CD8 + T-cell infiltration [158, 159]. Beyond intrinsic evasion, the JAK-STAT pathway remodels the TIME by manipulating multiple immune cell populations (Fig. 4 ). T cells form the core of anti-tumor immunity, and their intrinsic JAK-STAT status directly dictates tumor dynamics. The CUB domain-containing protein 1 (CDCP1) binds to T cells and suppresses internal JAK-STAT signaling, weakening cytotoxic T lymphocytes (CTLs) while inducing regulatory T cells (Tregs)—a feedback loop critical for renal cell carcinoma progression [160, 161]. Antigen presentation is also severely compromised. The TME tends to disrupt the balance between STAT3 and STAT5 within dendritic cells (DCs).Concurrently, JAK/STAT3 signaling plays a major role in driving polarization of tumor-associated macrophages (TAMs) toward the pro-tumorigenic M2 phenotype [162, 163]. Tumor-derived cytokines, including LIF, CSF-1, and IL-6, together with metabolites and exosomal non-coding RNAs, sustain JAK/STAT3 activation within TAM populations [158, 164–171]. This signaling program promotes immunosuppressive macrophage functions, enhances tumor cell survival, and facilitates metastatic progression. In addition, inflammatory crosstalk within the tumor microenvironment further reinforces these effects. Cytokines such as IL-1β and TNF-α induce phenotypic remodeling of cancer-associated fibroblasts (CAFs), stimulating IL-6 secretion and further amplifying macrophage-associated JAK/STAT3 signaling. Macrophage-derived IL-6 can subsequently activate tumor-intrinsic STAT3 signaling, contributing to B7-H4-associated immune suppression and transcriptional upregulation of pro-metastatic mediators such as FoxQ1 through repression of miR-506-3p. Fig. 4Multicellular crosstalk in the TME orchestrated by JAK/STAT signaling. (A) Dysfunction of T lymphocytes and dendritic cells (DCs). Tumor-derived CDCP1 interacts with the CD6 receptor on CD8+ T cells to suppress internal JAK/STAT signaling, impairing cytotoxic activity. Simultaneously, regulatory T cells (Tregs) interact with DCs via the CCR8-CCR5 axis, inhibiting JAK/STAT activation and IL-12 secretion in DCs, thereby blunting adaptive anti-tumor immunity. (B) The CAF-macrophage-tumor signaling network. Pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) drive the transformation of fibroblasts into cancer-associated fibroblasts (CAFs). Concurrently, tumor-derived exosomes suppress SOCS expression in macrophages, fostering JAK/STAT3 hyperactivation and M2-like polarization. Macrophage-secreted IL-6, enhanced by B7-H4 signaling, activates tumor-intrinsic STAT3 to repress miR-506-3p, ultimately upregulating the oncogene FoxQ1 to promote progression. (C) Neutrophil metabolic reprogramming. Tumor-secreted GM-CSF activates the JAK/STAT-C/EBPβ axis in neutrophils, inducing the expression of the metabolic enzyme ACOD1. This metabolic reconfiguration sustains a pro-metastatic environment and supports cancer cell survival Multicellular crosstalk in the TME orchestrated by JAK/STAT signaling. (A) Dysfunction of T lymphocytes and dendritic cells (DCs). Tumor-derived CDCP1 interacts with the CD6 receptor on CD8+ T cells to suppress internal JAK/STAT signaling, impairing cytotoxic activity. Simultaneously, regulatory T cells (Tregs) interact with DCs via the CCR8-CCR5 axis, inhibiting JAK/STAT activation and IL-12 secretion in DCs, thereby blunting adaptive anti-tumor immunity. (B) The CAF-macrophage-tumor signaling network. Pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) drive the transformation of fibroblasts into cancer-associated fibroblasts (CAFs). Concurrently, tumor-derived exosomes suppress SOCS expression in macrophages, fostering JAK/STAT3 hyperactivation and M2-like polarization. Macrophage-secreted IL-6, enhanced by B7-H4 signaling, activates tumor-intrinsic STAT3 to repress miR-506-3p, ultimately upregulating the oncogene FoxQ1 to promote progression. (C) Neutrophil metabolic reprogramming. Tumor-secreted GM-CSF activates the JAK/STAT-C/EBPβ axis in neutrophils, inducing the expression of the metabolic enzyme ACOD1. This metabolic reconfiguration sustains a pro-metastatic environment and supports cancer cell survival Beyond macrophages, the JAK-STAT pathway also orchestrates the pro-metastatic reprogramming of other immune cells. In metastatic niches, tumor-secreted GM-CSF drives ACOD1 expression in neutrophils through the JAK/STAT-C/EBPβ signaling axis. This metabolic reprogramming promotes cancer cell survival and contributes to the establishment of pre-metastatic niches. Similarly, PD-L1 on lung cancer cells can trigger “reverse signaling” through intracellular JAK2/STAT3 activation, inducing IL-6 secretion and recruitment of myeloid-derived suppressor cells (MDSCs). Subsequent JAK2/STAT3 signaling within MDSCs upregulates S100A8/A9 expression, sustaining immunosuppressive activity and limiting effector T-cell infiltration [172, 173]. The JAK-STAT signaling pathway and drug resistance In addition to its role in immune evasion, aberrant JAK-STAT signaling contributes to both intrinsic and acquired resistance to chemotherapy, targeted therapy, and radiotherapy. Through coordinated regulation of survival signaling, metabolic adaptation, tumor-stroma interactions, and cellular plasticity, persistent JAK/STAT activation establishes a multidimensional resistance network associated with treatment failure [174–176]. One major mechanism underlying this phenotype involves transcriptional upregulation of anti-apoptotic genes. Sustained STAT3 and STAT5 signaling promotes expression of pro-survival mediators, including BCL2, BCL-xL, MCL1, and Survivin, thereby limiting apoptosis following genotoxic stress induced by agents such as cisplatin and doxorubicin [177, 178]. Consequently, tumor cells retain the capacity to survive DNA damage and recover proliferative potential following treatment exposure. Beyond apoptosis resistance, JAK/STAT signaling also promotes therapeutic resistance through induction of cellular plasticity and enrichment of cancer stem cell (CSC) populations. In inflammatory tumor microenvironments, IL-6- or HERC2-mediated activation of the JAK2/STAT3 axis transcriptionally induces stemness-associated regulators, including NANOG and SOX2, as well as anti-apoptotic genes [191]. This transcriptional and epigenetic reprogramming promotes CSC-like phenotypes in breast and hepatocellular carcinoma cells, contributing to resistance to targeted therapies such as sorafenib and platinum-based chemotherapy. Metabolic adaptation represents another important component of JAK/STAT-mediated drug resistance, particularly through suppression of ferroptotic cell death pathways [179]. In triple-negative breast cancer (TNBC), the HLF/IL-6/JAK/STAT3 axis mediates protective crosstalk between tumor cells and macrophages, reducing intracellular lipid reactive oxygen species (ROS) accumulation and limiting ferroptosis induction during chemotherapy exposure [180]. These findings highlight the role of JAK/STAT signaling in integrating inflammatory and metabolic programs that support treatment tolerance. Importantly, resistance mechanisms mediated by JAK/STAT signaling are not solely tumor-intrinsic but are also reinforced by paracrine interactions within the tumor microenvironment. Cytokine- and kinase-dependent feedback circuits, including the MELK-CSF1 and LIF-CXCL16 axes, sustain pro-survival signaling during therapeutic intervention [158, 171]. Consequently, combination strategies incorporating JAK/STAT pathway inhibitors alongside chemotherapy or targeted therapies may simultaneously disrupt tumor-intrinsic survival programs and microenvironment-derived resistance signals, thereby enhancing therapeutic sensitivity in refractory tumors. JAK-STAT signaling pathway and cancer treatment Aberrant activation of the JAK/STAT signaling pathway contributes to tumor progression, metastasis, therapeutic resistance, and immune evasion across multiple cancer types. Advances in understanding tumor heterogeneity and TME dynamics have expanded therapeutic strategies targeting this pathway beyond conventional kinase inhibition. Current approaches include blockade of upstream cytokine-receptor signaling, selective inhibition of JAK kinase activity, modulation of downstream STAT-dependent transcriptional programs (Fig. 5 ), and emerging strategies targeting pathway-associated epigenetic and post-transcriptional regulatory mechanisms (Table 4). Fig. 5herapeutic targeting of the JAK/STAT signaling axis in cancer. (A) Upstream Blockade: Strategies involve neutralizing cytokines and blocking receptors via monoclonal antibodies (e.g., siltuximab), or inducing receptor degradation and preventing complex assembly using natural compounds like capsaicin. (B) Midstream Kinase Inhibition: Small-molecule JAK inhibitors (e.g., ruxolitinib) abrogate kinase activation. The inset highlights that JAK1 inhibition also promotes PD-L1 proteasomal degradation by impairing STT3A-mediated glycosylation. (C) Downstream Effector Intervention: Inhibitors targeting STAT transcription factors prevent their phosphorylation, dimerization, and nuclear translocation, thereby suppressing the expression of pro-survival and metastatic genes (e.g., Bcl-2, VEGF) herapeutic targeting of the JAK/STAT signaling axis in cancer. (A) Upstream Blockade: Strategies involve neutralizing cytokines and blocking receptors via monoclonal antibodies (e.g., siltuximab), or inducing receptor degradation and preventing complex assembly using natural compounds like capsaicin. (B) Midstream Kinase Inhibition: Small-molecule JAK inhibitors (e.g., ruxolitinib) abrogate kinase activation. The inset highlights that JAK1 inhibition also promotes PD-L1 proteasomal degradation by impairing STT3A-mediated glycosylation. (C) Downstream Effector Intervention: Inhibitors targeting STAT transcription factors prevent their phosphorylation, dimerization, and nuclear translocation, thereby suppressing the expression of pro-survival and metastatic genes (e.g., Bcl-2, VEGF) Table 4Landscape of therapeutic modalities targeting the JAK/STAT signaling pathway in cancerAgent / StrategyTargetIndications / ModelsDevelopment Stage & Status (Trial IDs)Ref.Upstream Cytokine & Receptor BlockadeSiltuximabIL-6NSCLC, Ovarian cancerPreclinical[182, 261]TocilizumabIL-6RPancreatic carcinoma; ICI-induced irAEsPhase II, Completed (NCT02767557, NCT03601611)[187, 262]Natural modulators (e.g., Capsaicin, Diacerein, Oxymatrine)gp130, IL-6R, IL-21RSolid tumors, Breast cancer, Gastric cancerPreclinical[195–197]IL-4 / IL-13 antagonistsSTAT6 (via IL-4/13)Hodgkin’s lymphomaPreclinical[191–193]JAK Kinase InhibitorsRuxolitinibJAK1/2Myelofibrosis, Polycythemia Vera, GvHDApproved / Phase III, Completed (NCT00952289, NCT01243944, NCT02953678)[199, 200, 219, 220]MomelotinibJAK1/2, ACVR1Myelofibrosis, Post-polycythemia VeraPhase III, Completed (NCT04173494)[203]AZD4205 (Golidocitinib)JAK1Adv. NSCLC (+ osimertinib), Relapsed PTCLPhase II, Completed (NCT03450330, NCT04105010)N/AFedratinibJAK2Primary myelofibrosis (+ nivolumab)Phase I, Completed (NCT05393674)[217]ItacitinibJAK1Acute GvHD and CRSPhase I/II, Completed (NCT03139604)N/APreclinical JAKi (e.g., AZD1480, CJ14939)JAK1/2Prostate, Lung, Colorectal cancerPreclinical[210–212]STAT Inhibitors & ModulatorsOPB-series (OPB-31121, OPB-51602)STAT3Advanced Cancers / Solid TumorsPhase I, Completed (NCT00955812, NCT01423903)N/ATTI-101STAT3Breast, HNSCC, NSCLC, HCCPhase I/II, Recruiting (NCT03195699)[225]WP-series (WP1066, WP1220)JAK2/STAT3Brain Metastasis, Glioma, CTCLPhase I/Ib, Recruiting (NCT01904123, NCT04702503)[226]PyrimethamineSTAT3Relapsed CLL / SLLPhase I/II, Completed (NCT01066663)N/APreclinical dual inhibitors (e.g., Alantolactone)STAT3 / EGFRPancreatic cancer, Solid tumorsPreclinical[214, 215, 231]LLL12 / AS1517499STAT3 / STAT6Various solid models, Inflammatory BCPreclinical[224, 235]Emerging ModalitiesAZD9150 / IONIS-STAT3RxSTAT3 mRNAAdv. Cancers, Metastatic HCC, DLBCLPhase I/II, Dose-escalation (NCT01839604, NCT01563302)[236]STAT3-targeting PROTACsSTAT3Solid tumorsPreclinicalN/ARuxolitinib nanocrystalsJAK/STATAging tumor / stromal cellsPreclinical[237] Table 4Landscape of therapeutic modalities targeting the JAK/STAT signaling pathway in cancerAgent / StrategyTargetIndications / ModelsDevelopment Stage & Status (Trial IDs)Ref.Upstream Cytokine & Receptor BlockadeSiltuximabIL-6NSCLC, Ovarian cancerPreclinical[182, 261]TocilizumabIL-6RPancreatic carcinoma; ICI-induced irAEsPhase II, Completed (NCT02767557, NCT03601611)[187, 262]Natural modulators (e.g., Capsaicin, Diacerein, Oxymatrine)gp130, IL-6R, IL-21RSolid tumors, Breast cancer, Gastric cancerPreclinical[195–197]IL-4 / IL-13 antagonistsSTAT6 (via IL-4/13)Hodgkin’s lymphomaPreclinical[191–193]JAK Kinase InhibitorsRuxolitinibJAK1/2Myelofibrosis, Polycythemia Vera, GvHDApproved / Phase III, Completed (NCT00952289, NCT01243944, NCT02953678)[199, 200, 219, 220]MomelotinibJAK1/2, ACVR1Myelofibrosis, Post-polycythemia VeraPhase III, Completed (NCT04173494)[203]AZD4205 (Golidocitinib)JAK1Adv. NSCLC (+ osimertinib), Relapsed PTCLPhase II, Completed (NCT03450330, NCT04105010)N/AFedratinibJAK2Primary myelofibrosis (+ nivolumab)Phase I, Completed (NCT05393674)[217]ItacitinibJAK1Acute GvHD and CRSPhase I/II, Completed (NCT03139604)N/APreclinical JAKi (e.g., AZD1480, CJ14939)JAK1/2Prostate, Lung, Colorectal cancerPreclinical[210–212]STAT Inhibitors & ModulatorsOPB-series (OPB-31121, OPB-51602)STAT3Advanced Cancers / Solid TumorsPhase I, Completed (NCT00955812, NCT01423903)N/ATTI-101STAT3Breast, HNSCC, NSCLC, HCCPhase I/II, Recruiting (NCT03195699)[225]WP-series (WP1066, WP1220)JAK2/STAT3Brain Metastasis, Glioma, CTCLPhase I/Ib, Recruiting (NCT01904123, NCT04702503)[226]PyrimethamineSTAT3Relapsed CLL / SLLPhase I/II, Completed (NCT01066663)N/APreclinical dual inhibitors (e.g., Alantolactone)STAT3 / EGFRPancreatic cancer, Solid tumorsPreclinical[214, 215, 231]LLL12 / AS1517499STAT3 / STAT6Various solid models, Inflammatory BCPreclinical[224, 235]Emerging ModalitiesAZD9150 / IONIS-STAT3RxSTAT3 mRNAAdv. Cancers, Metastatic HCC, DLBCLPhase I/II, Dose-escalation (NCT01839604, NCT01563302)[236]STAT3-targeting PROTACsSTAT3Solid tumorsPreclinicalN/ARuxolitinib nanocrystalsJAK/STATAging tumor / stromal cellsPreclinical[237] Landscape of therapeutic modalities targeting the JAK/STAT signaling pathway in cancer At the same time, major therapeutic challenges—including systemic toxicity, off-target effects, compensatory pathway activation, and variable clinical responses—continue to limit durable treatment efficacy. Consequently, recent efforts have increasingly focused on the development of more selective and context-dependent therapeutic approaches, including targeted protein degraders, antisense oligonucleotides (ASOs), and immunomodulatory combination strategies. In the following sections, we discuss both clinically established therapies and emerging investigational approaches targeting JAK/STAT signaling in cancer. Blocking of upstream cytokines and enzymes In many solid tumors and hematologic malignancies, autocrine and paracrine cytokine networks sustain activation of JAK/STAT signaling. Therapeutic strategies targeting this level of regulation aim to disrupt upstream inflammatory signaling before downstream kinase activation and transcriptional reprogramming occur. Current approaches include clinically approved cytokine-targeting biologics and emerging small-molecule modulators under investigation in preclinical studies. IL-6 is an important mediator of tumor progression and inflammatory signaling in multiple cancers, including non-small cell lung cancer (NSCLC) and ovarian cancer [181]. The anti-IL-6 monoclonal antibody siltuximab, originally approved for Castleman disease, neutralizes IL-6 and prevents activation of the IL-6R/gp130 signaling complex [182]. This inhibition suppresses downstream JAK/STAT3 signaling and reduces expression of STAT3-dependent pro-survival mediators such as Bcl-2 and Survivin [183]. In preclinical NSCLC and ovarian cancer models, siltuximab treatment has also been associated with reduced angiogenesis and delayed tumor progression [164, 184]. Similarly, IL-6 receptor-targeting antibodies such as tocilizumab inhibit activation of the IL-6/JAK/STAT3 axis and are being explored in oncologic and immunomodulatory settings [182, 185]. Tocilizumab has also been evaluated in combination with conventional cytotoxic therapies to address inflammation-associated chemoresistance. For example, a randomized Phase II trial investigated the addition of tocilizumab to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer [186]. This strategy aimed to counteract IL-6-mediated pro-survival signaling and systemic inflammation, highlighting the role of the IL-6/JAK/STAT3 axis in orchestrating both tumor progression and cancer-related cachexia. Beyond these direct anti-tumor efforts, targeting this axis has gained significant attention as a strategy for immunomodulation and toxicity management. Recent clinical insights from the COLAR trial demonstrate that tocilizumab effectively treats checkpoint inhibitor (ICI)-induced colitis and arthritis [187]. These findings suggest that IL-6 blockade may reduce immune-related adverse events (irAEs) while preserving anti-tumor immune responses in selected clinical contexts [187]. Mechanistically, IL-6/JAK1 signaling also regulates PD-L1 stability through post-translational modification pathways involving STT3A-mediated glycosylation [188, 189]. Accordingly, JAK1 inhibition can promote PD-L1 degradation and enhance CD8 + T-cell cytotoxic activity [190]. Collectively, these observations support continued investigation of IL-6/JAK-targeted approaches as combination strategies in cancer immunotherapy. Targeting inflammatory cytokine signaling within the tumor microenvironment may also improve sensitivity to chemotherapy and targeted therapy. In Hodgkin’s lymphoma (HL), microenvironmental IL-4 and IL-13 activate the JAK/STAT6 axis, leading to the upregulation of Bcl-xL and resistance to doxorubicin. The application of IL-4/IL-13 pathway antagonists can specifically block STAT6 phosphorylation and restore tumor cells’ sensitivity to apoptosis [191–193]. However, a persistent challenge in the clinical translation of these upstream inhibitors remains the risk of systemic toxicity and the emergence of compensatory activation of alternative signaling pathways, necessitating more precise patient stratification based on cytokine expression profiles. Several natural compounds and small-molecule agents are also being investigated for their ability to modulate upstream cytokine signaling and protein homeostasis. Capsaicin induces endoplasmic reticulum stress and promotes proteasomal degradation of gp130, thereby suppressing IL-6-mediated JAK/STAT3 activation [194, 195]. Diacerein disrupts IL-6/IL-6R complex assembly and reduces expression of invasion-associated proteins including MMP-9 [196]. In addition, oxymatrine inhibits the IL-21/JAK2/STAT3 axis by downregulating receptor expression and has been reported to reverse EMT-associated phenotypes in gastric cancer models [197]. CDCP1 has also emerged as a potential upstream regulator of JAK2/STAT3 signaling, with experimental evidence suggesting that its inhibition may partially restore anti-tumor T-cell activity [160]. Evolution and expansion of JAK kinase inhibitors Members of the JAK kinase family (JAK1, JAK2, JAK3, and TYK2) serve as central mediators linking extracellular cytokine signaling to downstream transcriptional programs [198]. Therapeutic strategies targeting these kinases have evolved from first-generation ATP-competitive inhibitors toward more selective agents, combination regimens, and emerging approaches, including allosteric inhibitors and targeted protein degraders. These developments aim to improve therapeutic selectivity, reduce systemic toxicity, and overcome resistance mechanisms associated with tumor heterogeneity, compensatory signaling pathways, and microenvironment-mediated survival programs. Importantly, interpretation of these approaches requires careful distinction between clinically validated therapies and emerging preclinical concepts. In hematological malignancies, JAK inhibitors have become established therapeutic agents in clinical hematology. The core mechanism lies in precisely reversing the constitutive activation of the kinase JH1 domain caused by functional gain-of-function mutations (such as JAK2 V617F). The first approved I-type inhibitor, ruxolitinib, demonstrated clinical efficacy in controlling hematocrit and alleviating hypercytokinemia in the treatment of myelofibrosis (validated by the landmark COMFORT-I trial) [199] and polycythemia vera refractory to hydroxyurea (demonstrated in the RESPONSE trial) [200] through physically occupying the ATP binding pocket [201, 202]. Meanwhile, for the dose-limiting anemia caused by ruxolitinib, the next-generation inhibitor momelotinib (recently validated in the Phase 3 MOMENTUM trial) [203] successfully restored iron homeostasis through dual inhibition of ACVR1/ALK2, thereby achieving dual regulation of metabolism and signal transduction [204]. However, tumor heterogeneity and specific acquired mutations pose significant therapeutic challenges. For instance, certain JAK mutants do not respond to standard JAK inhibitors; the JAK3 Q988P mutation, unlike most JAK3 mutants, does not require a functionally active JAK1 protein and is therefore inherently resistant to ruxolitinib, highlighting the need for precise genomic profiling in clinical practice [205]. Furthermore, the intervention for hematological tumors is extending deeply to the epigenetic level. Compensatory activation of IL-6/JAK/STAT3 signaling has been implicated as a resistance mechanism limiting the efficacy of JAK inhibitor monotherapy in selected hematologic malignancies [206]. In preclinical models, the combination of histone deacetylase inhibitors [207] or p300/CBP inhibitors (such as A-485, GNE-049) specifically blocks STAT3 acetylation and nuclear translocation, thereby suppressing compensatory STAT3-dependent survival signaling [208, 209]. Similar synergistic effects have been observed in early clinical settings when combining BET inhibitors (such as pelabresib) with ruxolitinib by blocking the transcriptional recruitment of the epigenetic “reader” protein to oncogenes, not only significantly enhancing the killing of malignant cells but also reducing hematological toxicity. With advancing research, the application strategies of JAK inhibitors in solid tumors have gone beyond a single cytotoxic effect, transforming into multi-dimensional regulation of tumor stemness, metabolic homeostasis, and chemotherapy sensitivity. While many of these concepts remain preclinical, targeted clinical trials are bridging this gap. In the preclinical setting for lung cancer and colorectal cancer, JAK inhibitors (such as CJ14939) exhibit excellent chemotherapy sensitization effects via inhibiting the p-JAK/p-STAT3 axis, effectively overcoming the acquired resistance of tumors to conventional chemotherapy [210, 211]. Clinically, highly selective inhibitors are being evaluated in rational combinations; for instance, a recent study assesses the oral JAK1 inhibitor AZD4205 in combination with osimertinib in advanced non-small cell lung cancer to overcome STAT3-mediated bypass resistance to EGFR-TKIs. Moreover, by blocking the JAK2 signaling axis, preclinical inhibitors such as AZD1480 can target the tumor stem cell subpopulation in prostate cancer and prevent clonal recovery after chemotherapy [212, 213]. At the metabolic level, natural compounds such as baicalein and alantolactone disrupt the redox balance mediated by JAK2/STAT3, leading to ROS accumulation and triggering ferroptosis [214, 215]. In the specific microenvironmental context of solid tumors, JAK1/TYK2 inhibitors can antagonize immunosuppressive signals, promoting the polarization of tumor-associated macrophages (TAMs) from the pro-tumor M2 type to the pro-inflammatory M1 type. However, the systemic toxicity and off-target immunosuppression associated with continuous pan-JAK inhibition remain major translational hurdles in solid tumors. In immunotherapy settings, JAK inhibitors exhibit context-dependent immunomodulatory effects that may either enhance anti-tumor immunity or suppress pathological inflammatory responses. On the one hand, the phosphorylation mediated by JAK1 (at the Y112 site) is a key switch for maintaining the glycosylation modification and stability of PD-L1. The application of JAK inhibitors can achieve the “functional depletion” of PD-L1 [216], blocking immune escape at the post-transcriptional level [190]. Preclinical and Phase I clinical trials have shown that the combination of JAK inhibitors with PD-1 blockades (such as the clinical evaluation of fedratinib in combination with nivolumab) [217] not only reduces the aggregation of MDSCs but also promotes the expansion of effector memory T-cell expansion, thereby reversing the resistance state of immune checkpoint blockade therapy [17, 172, 217, 218]. Additionally, the potent immunomodulatory effects of JAK inhibitors have been clinically validated in managing severe immune-related toxicities. Trials such as REACH-1 [219] and REACH3 [220] have established ruxolitinib as a highly effective therapy for steroid-refractory acute and chronic Graft-Versus-Host Disease (GvHD). Similarly, the GRAVITAS-301 trial [221] has explored itacitinib as prophylaxis for acute GvHD and cytokine release syndrome (CRS), demonstrating that targeted JAK1 blockade can curb pathological hyperinflammation without eliminating the desired immune effector cells. Despite these advances, clinical application of JAK inhibitors continues to face important challenges, including systemic toxicity, compensatory activation of parallel signaling pathways, and intra-tumoral heterogeneity. Emerging strategies, such as allosteric inhibitors and targeted protein degraders, including JAK- and STAT-directed PROTACs, are being investigated to improve selectivity and overcome resistance associated with ATP-competitive inhibition [205]. Unlike conventional kinase inhibitors, targeted degraders may also interfere with non-catalytic scaffolding functions of signaling proteins, thereby expanding therapeutic opportunities in resistant disease settings. Collectively, these developments illustrate the ongoing evolution of JAK-targeted therapies from broad kinase inhibition toward more context-specific and mechanism-oriented therapeutic strategies. Downstream effector intervention Therapeutic strategies targeting downstream STAT effectors and associated regulatory networks are being actively investigated as alternatives to upstream kinase inhibition. Because resistance to JAK inhibitors may arise through compensatory pathway activation and signaling redundancy, direct targeting of STAT transcription factors or their post-transcriptional regulatory mechanisms has emerged as a potential strategy to overcome tumor heterogeneity and therapeutic resistance. Importantly, distinct STAT family members exhibit context-dependent biological functions; while STAT1 is frequently associated with anti-tumor immunity and interferon signaling, STAT3 and STAT5 more commonly promote oncogenic transcriptional programs. Consequently, the development of selective inhibitors that suppress STAT3/5 activity while preserving beneficial STAT1-mediated immune functions remains a major therapeutic challenge. Thus far, pharmacological interventions targeting the core oncogenic factor STAT3 have undergone substantial preclinical and early clinical development [222, 223], aiming to challenge the traditional perception that “transcription factors are not druggable”. To accurately assess the maturity of these therapies, it is crucial to distinguish between preclinical findings and clinically validated approaches. In preclinical studies, the non-peptide small molecule inhibitor LLL12 has demonstrated selective inhibition of STAT3 signaling. It specifically binds to the SH2 domain of STAT3, physically blocking the tyrosine phosphorylation (Tyr705) and dimerization in various cancer models [224]. In the clinic, several direct STAT3 inhibitors have entered early-phase clinical trials. For instance, the Phase 1 trial of OPB-51,602 evaluated its safety in subjects with advanced solid tumors, while TTI-101, a novel oral STAT3 inhibitor, is currently being investigated in Phase 1 trials for patients with advanced cancers [225]. Furthermore, drug repurposing has emerged as a pragmatic clinical strategy; pyrimethamine, traditionally an antimicrobial agent, is being evaluated in a Phase 1/2 clinical trial for the treatment of relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) due to its newly identified STAT3-inhibitory properties. Specialized formulations and tissue-penetrant inhibitors are also being explored to improve therapeutic delivery within challenging tumor microenvironments. The potent JAK2/STAT3 dual inhibitor WP1066, which can penetrate the blood-brain barrier, is currently in a Phase 1 trial treating patients with recurrent malignant glioma or progressive metastatic melanoma in the brain [226]. This drug not only blocks STAT3 phosphorylation and downregulates downstream oncogenic genes (Bcl-xL, VEGF) but also activates anti-tumor immunity by inhibiting PD-L1 expression, thereby influencing both tumor cell survival and anti-tumor immune responses [227]. Similarly, topical applications are being explored to minimize systemic toxicity; the Study of WP1220 (a STAT3 inhibitor) formulated as an ointment is being evaluated in a Phase 1 trial in adult subjects with cutaneous T-cell lymphoma (CTCL). Besides, restoring the endogenous negative regulatory mechanism is a promising preclinical strategy; simulating or restoring the function of MLKL (the natural “molecular brake” of STAT3) with drugs may help curb the malignant progression of intestinal tumors [228]. Disruption of EGFR-STAT3 crosstalk has emerged as a potential strategy to overcome resistance to EGFR-targeted therapies. Simply inhibiting EGFR often leads to the feedback over-activation of STAT3 in pancreatic cancer or lung cancer cells through JAK kinases or other bypass pathways [184, 229, 230]. In preclinical evaluations, the natural sesquiterpene lactone compound alantolactone has been proven to effectively cutting off this escape path. When used in combination with EGFR inhibitors (such as erlotinib) in pancreatic cancer, it demonstrates a “synergistic lethality effect” [231]. A more refined chemical design has led to new dual inhibitors based on the thieno[2,3-d]pyrimidine core. These compounds can simultaneously downregulate p-EGFR and p-STAT3 levels, disrupt mitochondrial membrane potential, and activate the Caspase-3/7 cascade, providing a dual-target solution to overcome single-drug resistance [232]. Despite these rational designs, clinical translation is often hindered by tumor heterogeneity and the risk of off-target systemic toxicities, highlighting the need for careful dosage optimization and patient stratification. In addition to directly killing tumor cells, targeting the STAT pathway plays a vital role in reshaping the TME and reversing resistance to radiotherapy and chemotherapy [233, 234]. In the microenvironment of inflammatory breast cancer (IBC), IL-4 and IL-13 activate the JAK/STAT6 axis in macrophages, driving their polarization towards the immunosuppressive M2 phenotype. The preclinical application of the STAT6-specific inhibitor AS1517499 can block the phosphorylation at the Tyr641 site, inhibit the M2 transformation of macrophages, and thereby relieve the protective TME [235]. Looking ahead, overcoming the structural ‘undruggability’ of STAT proteins requires novel molecular modalities that expand beyond traditional small molecules to include nucleic acid therapeutics and targeted degradation. Antisense oligonucleotides (ASOs) have successfully entered clinical evaluation; for example, AZD9150 (IONIS-STAT3Rx), a next-generation ASO targeting STAT3 mRNA, is currently in Phase I/Ib and Phase 1/2 dose-escalation studies for patients with advanced cancers and metastatic hepatocellular carcinoma (HCC), offering a strategy to deplete the target at the transcript level [236]. Proteolysis Targeting Chimeras (PROTACs) have also emerged as a promising investigational strategy. STAT3-targeting PROTACs hijack the intracellular ubiquitin-proteasome system to promote STAT3 degradation, thereby disrupting both transcriptional and non-catalytic scaffolding functions. This approach specifically addresses the compensatory pathway activation and resistance mechanisms that plague conventional ATP-competitive or SH2-domain inhibitors. Moreover, the integration of nanotechnology and non-coding RNA is reshaping the treatment paradigm. Intelligent responsive multifunctional nanocrystal systems specifically block the JAK/STAT cascade within aging tumor cells and stromal cells [237]. Targeting the CircRNA-JAK/STAT axis is an emerging area of investigation in epigenetic therapy that may help overcome resistance to existing small-molecule inhibitors [238]. Collectively, these developments illustrate the growing integration of biomarker-guided therapeutic selection, targeted protein degradation, and RNA-directed therapies into strategies to modulate JAK/STAT signaling in cancer. Conclusion and outlook In summary, aberrant JAK-STAT signaling plays a central role in tumor progression, immune evasion, therapeutic resistance, and remodeling of the tumor microenvironment across multiple malignancies. Expanding understanding of non-canonical signaling mechanisms, epigenetic regulation, and immune-stromal crosstalk has broadened current perspectives beyond conventional kinase inhibition and highlighted the complexity of context-dependent JAK/STAT signaling networks. Despite substantial progress, several important biological and translational questions remain unresolved. First, the tumor-specific regulatory logic underlying non-canonical JAK/STAT signaling, including organelle-associated localization, liquid-liquid phase separation, and JAK-independent activation, remains incompletely understood. Second, heterogeneous patterns of pathway dysregulation and compensatory signaling across different tumor types continue to complicate the development of selective therapeutic strategies. Third, the interactions between JAK/STAT signaling, senescence-associated secretory phenotypes (SASP), and immunosuppressive tumor microenvironments require further mechanistic clarification. In addition, epigenetic and post-transcriptional regulation of endogenous negative regulators such as SOCS and PIAS remains insufficiently characterized. Important translational challenges also persist, including systemic toxicity associated with pan-JAK inhibition, the emergence of acquired resistance, the limited selectivity of current inhibitors, and the difficulty of therapeutically targeting non-canonical signaling functions. Continued integration of biomarker-guided patient stratification, selective pathway modulation, and combinatorial therapeutic approaches will likely be required to improve clinical efficacy. Collectively, ongoing investigations into canonical and non-canonical JAK/STAT signaling are expected to further refine therapeutic strategies targeting this pathway in cancer.